Imaging Technology News

Ardent Health, Fujifilm Team Up to Deliver Enterprise Imaging Solutions

tim.hodson — Thu, 14 May 2026 19:20:26 +0000

tim.hodson Thu, 05/14/2026 - 14:20

May 14, 2026 — Ardent Health, a provider of healthcare in mid-sized urban communities across the U.S., has partnered with Fujifilm Healthcare Americas Corp. to implement its Synapse enterprise imaging solutions across Ardent's acute care hospital footprint across six states.

Fujifilm’s Synapse Enterprise Imaging solutions will provide Ardent clinicians with a single, holistic view of patient imaging data across various departments, including radiology and cardiology, through a unified Fujifilm Synapse Diagnostic PACS viewer. Having centralized access to all patient imaging in Synapse VNA improves workflow efficiency by streamlining operations across different departments, fostering deeper collaboration across multidisciplinary teams, and in turn, contributing to high-quality care delivery.

“Ardent has a deep commitment to deploy technologies that improve quality and access to care in meaningful, measurable ways, while removing administrative barriers that weigh on physicians,” said Ardent Health Chief Medical Officer FJ Campbell, MD. “We’re pleased to partner with a technology leader that supports every part of patient imaging and data acquisition across our enterprise. Fujifilm’s informatics solutions give our clinicians the reliable, interoperable, and clear diagnostic insights they need, while easing documentation demands that often lead to fatigue.”

“We are very pleased to partner with Ardent Health on their enterprise imaging transformation and believe our technology portfolio aligns well with Ardent’s vision for a more secure, efficient and collaborative workspace for their users and a world class imaging experience for their patients” says Bill Lacy, senior vice president, medical informatics global business, FUJIFILM Healthcare Americas Corporation. “Ardent Health is setting a precedent by investing in our highly secure, AI-powered Synapse Enterprise Imaging solutions. Our mutual goals are to bring automation to imaging workflows, intelligence for critical case prioritization while reducing manual tasks, and deliver faster result turnaround times in a system designed with a focus on the user experience.”

Fujifilm Synapse

Fujifilm’s 7x enterprise imaging diagnostic PACS viewer allows for one user interface to extend across radiology, mammography and cardiology bringing unrivaled clinical and IT benefits for enterprise-wide imaging management. Having Synapse Enterprise PACS implemented across radiology and cardiology departments with Synapse VNA at the core enables healthcare organizations to more effectively manage growing and diverse departmental datasets, including non-DICOM specialty data. With Synapse Mobility, Ardent care teams will be able to see the patient’s full imaging record at any time, from anywhere, through their Epic EHR and on any mobile device.

Fujifilm’s integration with Epic Systems Corporation also supports seamless data flow between Synapse PACS and Epic’s industry’s leading electronic health record platform. This allows clinicians to view all medical images directly within the familiar Epic interface by creating a single, comprehensive patient imaging record. The integration also streamlines workflows by eliminating the need to jump between different systems to access data reports, and images, improves care coordination, reduces data silos, and supports AI-driven diagnostics across the entire healthcare enterprise, from acquisition to viewing.

Thursday, May 14, 2026 - 14:20

PNY Technologies

Bbmurray — Tue, 12 May 2026 21:21:04 +0000

Bbmurray Tue, 05/12/2026 - 16:21

Philips Introduces Titanion MRI System

tim.hodson — Tue, 12 May 2026 19:15:25 +0000

tim.hodson Tue, 05/12/2026 - 14:15

May 11, 2026 — Royal Philips is debuting Titanion MR, an ultra-high-gradient 3.0T MRI, at ISMRM 2026.

Titanion is designed to advance MRI beyond anatomical and functional imaging by enabling clinicians and researchers to apply quantitative and biologically informative imaging approaches. By combining ultra-high gradient performance with AI-enabled workflows, it will support the development and application of imaging biomarkers that reflect tissue microstructure and underlying biological processes across the body.

MRI continues to play an increasingly important role in diagnosis and disease monitoring. Philips Titanion MR is designed to advance this role by enabling imaging biomarkers that reflect tissue microstructure and function, supporting more precise and quantitative clinical insights across a range of applications, including neurology and oncology.

“Titanion MR represents a significant step forward for 3.0T MRI at Philips, expanding our ability to quantify imaging biomarkers across the body, especially in the brain, and bring advanced imaging capabilities into routine clinical practice,” said Ioannis Panagiotelis, Business Leader Magnetic Resonance at Philips. “By combining ultra-high gradient performance with advanced AI-powered software, we are helping clinicians and researchers gain deeper insight into tissue microstructure and underlying biology, supporting the next phase of MRI toward more precise and quantitative results, enabling increasingly proactive and personalized clinical insights.”

Imaging Biomarkers

Titanion is designed to bring ultra-high gradient performance to Philips’ 3.0T MRI portfolio, including:

Actual gradient strength of 150 mT/m gradient at slew rate of 250 T/m/s [2], enhancing visibility of microstructural tissue, advancing detailed research in neurodegenerative diseases
High G_rms performance, sustaining strong gradients over time to support advanced diffusion and microstructural imaging
Low eddy current design, providing exceptional signal fidelity and reducing image distortion for more reliable quantitative measurements
Large 55 cm field of view (FOV), enabling comprehensive anatomical coverage in a single exam, from brain to extremities, supporting true whole-body imaging

Together, these capabilities will enable advanced quantitative and microstructural imaging, supporting the development and broader clinical application of imaging biomarkers and their translation into more precise, data-driven clinical care and research.

Intelligent Performance

Titanion provides upgrades to Philips’ hardware innovation, combined with the company’s latest software advancements. With SmartSpeed Precise, users can achieve up to 80% sharper images [3] and up to 3x faster scan times [4], supporting productivity and diagnostic confidence.

Titanion is designed with operational efficiency in mind, with power requirements of only 115 kVA [X], supporting installation in a wider range of clinical environments without extensive infrastructure upgrades, helping bring high-performance MRI capabilities to more sites.

Availability and configuration options for Titanion will depend on existing MR configurations and customer environments.

Sources

Titanion is considered Work in Progress and is not FDA cleared or CE marked and not available for sale.
Pending verification
Compared to conventional (SENSE / Compressed SENSE / SmartSpeed AI) imaging. Sharpness was evaluated with phantom scanning.
Compared to Philips SENSE imaging.

Titanion MR

Tuesday, May 12, 2026 - 14:15

FDA Grants Clearance for Six Interventional Imaging Systems from Siemens Healthineers

tim.hodson — Tue, 12 May 2026 15:23:01 +0000

tim.hodson Tue, 05/12/2026 - 10:23

May 12, 2026 — Siemens Healthineers has received clearance from the Food and Drug Administration for six new systems in its Artis interventional imaging portfolio, which features the new Optiq AI imaging chain powered by artificial intelligence.

The new interventional systems include the floor, biplane, ceiling and pheno (or floor-mounted robotic) versions of the Artis vision platform; as well as the floor configurations of the Artis icono.explore and Artis genio platforms. The Optiq AI imaging chain common to all six systems uses AI to analyze and optimize image data in real time.

The six new systems address a wide range of clinical uses, operational needs, and financial considerations. The four systems in the Artis vision platform deliver high speed and precision for image‑guided procedures. The floor version of the Artis icono.explore is engineered for high patient throughput, and the Artis genio floor is a workhorse system designed for versatility and high productivity to handle a broad case mix. The unifying foundation across these six systems is the Optiq AI imaging chain, which meets the growing need for precision and premium image quality in image-guided procedures. Optiq AI applies deep‑learning‑based noise reduction across 2D imaging modes such as fluoroscopy, acquisition, and digital subtraction angiography. This denoising enables consistent, high-quality visualization during interventional procedures.

“As more complex procedures come to interventional labs, increased precision is of paramount importance,” said Kris McVey, head of Angiography in the Advanced Therapies business at Siemens Healthineers North America. “Our new Artis portfolio powered by Optiq AI delivers the high level of image quality clinicians rely upon to guide these intricate procedures—while taking into account the needs and budget of every type of healthcare facility.”

Additional Featues

Additional features in the Artis portfolio include advanced capabilities across procedures and a standardized user experience. Advanced 3D applications such as syngo DynaCT MORE reduce motion-related artifacts to enhance intraprocedural 3D imaging. The Touch UI touch screen enables tableside access to key system functions and supports direct, in‑case interaction as well as physician/technologist collaboration. Consistent controls across the portfolio help teams move between rooms with minimal variability.

To learn more, visit www.siemens-healthineers.com/en-us/angio/lp/artisicono

Photo: Siemens Healthineers

Tuesday, May 12, 2026 - 10:23

GE HealthCare Showcases AI-Powered MRI Technologies

tim.hodson — Mon, 11 May 2026 15:51:28 +0000

tim.hodson Mon, 05/11/2026 - 10:51

May 11, 2026 – At the International Society for Magnetic Resonance in Medicine (ISMRM) 2026 Annual Meeting, GE HealthCare is announcing advancements in research tools and MRI systems that aim to accelerate discovery, strengthen collaboration across research programs and turn innovation into meaningful clinical achievements.

GE HealthCare continues to invest in advanced MR technology with its next-generation SIGNA MR systems and research tools designed to help academic and clinical research programs move faster, work more collaboratively and push the boundaries of discovery. By combining high-performance hardware with advanced software and deep learning–based techniques, these innovations are intended to reduce scanning and examination times, improve image quality, and enable more consistent data across sites and studies.

The company's focus "is to enable the research ecosystem that helps researchers explore new questions, scale collaboration and translate discoveries more efficiently to broaden clinical impact,” said Kelly Londy, president and CEO, MR and Women’s Health at GE HealthCare. “From high-performance systems to collaboration resources for productive MR research, we are committed to giving researchers the tools they need to work together more effectively, explore new frontiers, and accelerate the path from discovery to patient experience.”

MRI AI-driven technologies

Expanding on GE HealthCare’s leadership in AI-enabled medical device 510(k) clearances,¹ GE HealthCare announced the U.S. FDA 510(k) pending status of its latest deep-learning acceleration technique, Sonic DL for 2D imaging beyond cardiac cine². Built on the foundation of previous Sonic DL technology for cardiac cine and 3D imaging, this latest solution will mean up to 85% of MR exams will benefit from the deep-learning acceleration of Sonic DL, which is further enhanced by compatibility with AIR Recon DL for 2D and 3D imaging and will further enhance image quality and Signal-to-Noise Ratio (SNR) of accelerated exams.

At the foundation of GE HealthCare’s latest MR capabilities is SIGNA One³, a new AI-powered, next-gen workflow ecosystem designed to simplify complexity, improve efficiency and enable more consistent imaging across clinical and research environments. By addressing inefficiencies throughout the MRI workflow, SIGNA One helps increase throughput, reduce variability, and improve the experience for researchers, technologists and patients alike.

SIGNA One integrates a suite of core workflow solutions, including an intuitive and AI-guided user experience designed to minimize training time and support users of varying experience levels, as well as one-click switching between clinical and research modes⁴ within an exam for seamless integration of research protocols within clinical workflows. Together, these capabilities are designed to support more seamless collaboration and reproducibility — critical enablers for advanced MR research programs.

Built on the SIGNA One platform, SIGNA Bolt⁵, GE HealthCare’s next-generation 510(k) cleared 3T MRI system, extends these capabilities with powerful performance grounded in deep learning and a focus on sustainability. The system is designed to streamline end-to-end imaging pathways, support precision diagnostics, and maintain low energy consumption and operational costs — reinforcing GE HealthCare’s commitment to advancing MR research and clinical innovation responsibly.

The new SIGNA Sprint with Freelium⁶ offers helium-free technology, eliminating vent pipe requirements, without compromising clinical or

Signa Sprint

operational efficiency. With less than 1% helium usage⁷, SIGNA Sprint with Freelium provides helium independence without driving higher power consumption requirements or sacrificing image quality.

Additionally, AIR Recon DL, GE HealthCare’s deep-learning reconstruction technology, is expanding with the addition of support for Zero Echo Time (ZTE) and Silenz low-acoustic noise imaging⁸. The basis for the MR bone imaging technique, oZTEo, ZTE imaging can provide images similar to CT — but without ionizing radiation — as well as novel applications such as lung imaging. AIR Recon DL will enable reduced scan time and improve the image quality of ZTE exams, while also enabling the potential for improved 3D volume rendering.

Research Collaboration

GE HealthCare also will introduce SIGNA Studio⁹, a suite of software development and collaboration resources for productive, impactful and efficient MR research. SIGNA Studio components are designed to make research tools more accessible and faster for researchers to deploy.

Building on early research collaborations, GE HealthCare announces two additional installations of the investigational MAGNUS prototype¹⁰, a head-only MR scanner designed to explore advancements in neuroscience, at both King’s College London (KCL) and West China Hospital to push the boundaries of microstructural imaging, advanced diffusion and functional techniques, amplified by GE HealthCare’s latest deep-learning technology including Sonic DL and AIR Recon DL.

“This installation at King’s College London represents an important step forward for neuroscience research,” said Dr. Steve Williams, Professor of Imaging Sciences at King’s College London, who will present during GE HealthCare’s lunch symposium at ISMRM. “This platform gives us the ability to investigate aspects of brain structure and function that were previously out of reach, helping advance our understanding of neurological disease and opening new research possibilities.”

GE HealthCare also continues to invest in advancing the neuro care pathway, spanning research, imaging, and clinical decision support. This includes the integration of icometrix and its icobrain platform to strengthen quantitative brain MRI analysis and support more personalized neurological care, particularly in areas such as Alzheimer’s disease.

References

U.S. Food and Drug Administration. “Artificial Intelligence-Enabled Medical Devices.” https://www.fda.gov/medical-devices/software-medical-device-samd/artifi….
Sonic DL for 2D imaging is 510(k) pending with the U.S. FDA. Not CE marked. Not available for sale in all regions.
SIGNA One Interface features are offered on select GE HealthCare MRI Systems. The features are 510(k) cleared. Not CE Marked. Not available in all markets.
Research mode is available as an option and not intended for clinical use. Research operation may require observation of national regulations.
SIGNA Bolt is 510(k) cleared. Not CE Marked. Not available in all markets.
SIGNA Sprint with Freelium is a sealed configuration of SIGNA Sprint Select. SIGNA Sprint Select is 510(k) cleared. Not CE Marked. Not available in all markets.
Compared to conventional magnets.
AIR Recon DL for ZTE imaging is 510(k) pending with the U.S. FDA. Not CE marked. Not available for sale in all regions.
SIGNA Studio is a set of tools for MR research and development use only. Not intended for clinical use. Research use may be subject to additional requirements in each country or jurisdiction. Not a product. Not for sale in any region.
Technology in development that represents ongoing research and development efforts. Not 510(k) cleared and not CE marked. Not for sale. Intended for investigational use only.

Monday, May 11, 2026 - 10:51

Bayer Announces Positive Data for Investigational PET Radiotracer

tim.hodson — Fri, 08 May 2026 15:24:44 +0000

tim.hodson Fri, 05/08/2026 - 10:24

May 7, 2026 — Bayer has announced positive topline results from the Phase III REVEAL study, an investigator-initiated study by Brigham and Women’s Hospital that evaluated the investigational PET radiotracer I 124 evuzamitide.^1,5The study met the primary endpoints of sensitivity (the ability of a test to identify individuals who have the condition) and specificity (the ability of a test to identify individuals who do not have the condition) for the diagnosis of cardiac amyloidosis based on visual scan interpretation.¹ Bayer plans to present the complete results at an upcoming scientific congress.

I 124 evuzamitide is an investigational PET radiotracer — a radioactive diagnostic imaging agent injected into the body before a PET scan to assist with visualization–being studied in patients with suspected cardiac amyloidosis.⁵ I 124 evuzamitide is an investigational compound and has not been approved by any health authority for use in any country for any indication.

The compound was previously granted Breakthrough Therapy Designation for PET imaging in patients with suspected or known cardiac amyloidosis² as well as Orphan Drug status for both light-chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) in the U.S. and the EU.³ Bayer plans to discuss the data and submission for regulatory approval with the FDA and other health authorities.

Data Results

“Cardiac amyloidosis is often under- or misdiagnosed,⁶ impacting patients’ ability to begin appropriate treatment earlier, when it may help prevent further organ damage,” said REVEAL principal investigator Dr. Sharmila Dorbala, Director of Nuclear Cardiology at Brigham and Women’s Hospital. “These I 124 evuzamitide data demonstrate the potential of a single test to help health care providers identify or exclude cardiac amyloidosis. Clinically, a sensitive, specific and quantitative PET tracer could help distinguish cardiac amyloidosis from other causes of heart failure, differentiate amyloid subtypes when used alongside appropriate laboratory testing, and track changes in cardiac amyloid burden over time.”

I 124 evuzamitide is one of two investigational amyloid radiotracers that Bayer acquired from Attralus, Inc. The compound is also known as AT-01. The acquisition, announced in early 2026, expanded Bayer’s radiology pipeline with complementary tracers targeting systemic amyloid disease and reinforced the company’s strategy to build a leading position in imaging for cardiovascular and other serious conditions.

“As a leader in radiology, we are committed to bringing forward options for earlier diagnosis of diseases such as cardiac amyloidosis for the benefit of patients,” said Dr. Konstanze Diefenbach, Head of Radiology Research & Development at Bayer’s Pharmaceuticals Division. “We are very excited about the positive topline results of the REVEAL study and are looking forward to sharing the data with the scientific community.”

Cardiac Amyloidosis

Cardiac amyloidosis is a severe, progressive disease caused by the accumulation of misfolded proteins (amyloid) in heart tissue, making it stiff and thick which can impair its ability to pump blood effectively.⁷ As the disease is underdiagnosed, current estimates state the condition impacts approximately 400,000 patients worldwide,⁸ though the number is likely greater. Without appropriate diagnosis and treatment, cardiac amyloidosis can lead to heart failure, frequent hospitalizations and early mortality.⁷

Currently, there is no single, non-invasive test that can reliably detect and diagnose cardiac amyloidosis or quantify and monitor myocardial amyloid burden. Despite increasing disease awareness by health care providers, a prolonged diagnostic journey is common,⁶ with patients often consulting several specialists and receiving multiple imaging procedures before an accurate diagnosis.

The REVEAL Study⁵

The REVEAL (“Research with EVuzamitide I 124 to Elucidate Cardiac AmyLoidosis”) study is an investigator-initiated Phase III clinical trial of the investigational diagnostic imaging agent I 124 evuzamitide in patients with suspected cardiac amyloidosis with Brigham and Women’s Hospital in Boston, MA, as the study sponsor.

The main purpose of the study was to evaluate the efficacy and safety of the investigational radiotracer I 124 evuzamitide for diagnosing cardiac amyloidosis in participants with suspected cardiac amyloidosis compared to clinical standard of care (SoC) diagnosis. Secondary analyses assessed diagnostic performance in ATTR and AL subtypes. The imaging test used in this study was a positron emission tomography computed tomography (PET/CT) scan.

REVEAL is a multicenter, open-label, single-arm Phase III study conducted at 19 centers in the United States, evaluating 170 adults with suspected cardiac amyloidosis.

Participants received a single intravenous dose of I 124 evuzamitide, followed by cardiac and partial-body PET/CT imaging, 3-5 hours post-injection. All PET/CT images were independently read by experienced cardiac PET physicians, assessing visual presence or absence of cardiac tracer uptake, blinded to clinical data. SoC diagnosis was independently adjudicated by clinical amyloidosis experts, blinded to PET results, using routine diagnostic data collected up to 60 days after imaging.

Diagnostic sensitivity and specificity of I 124 evuzamitide were determined using SoC diagnosis as the reference standard.

References

Data on file.
Beighley, S. (2024, August 5). Attralus receives breakthrough therapy designation for its Pan-Amyloid Diagnostic Pet Imaging candidate 124i-evuzamitide (AT-01) for cardiac amyloidosis. Attralus. https://attralus.com/press-releases/attralus-receives-breakthrough-therapy-designation-for-its-pan-amyloid-diagnostic-pet-imaging-candidate-124i-evuzamitide-at-01-for-cardiac-amyloidosis
Beighley, S. (2022, December 19). Attralus receives FDA and Ema Orphan designation for AT-01 (iodine (I-124) evuzamitide), an investigational diagnostic for the management of Al and Attr Amyloidosis. Attralus. https://attralus.com/press-releases/attralus-receives-fda-and-ema-orphan-designation-for-at-01-iodine-i-124-evuzamitide-an-investigational-diagnostic-for-the-management-of-al-and-attr-amyloidosis
Rozenbaum, M. H., Large, S., Bhambri, R., Stewart, M., Whelan, J., van Doornewaard, A., Dasgupta, N., Masri, A., & Nativi-Nicolau, J. (2021). Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review. Cardiology and Therapy, 10(1), 141-159. https://doi.org/10.1007/s40119-021-00219-5.
Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis (REVEAL). Clinicaltrials.gov. (n.d.). https://clinicaltrials.gov/study/NCT06788535
Dang D, Fournier P, Cariou E, Huart A, Ribes D, Cintas P, Roussel M, Colombat M, Lavie-Badie Y, Carrié D, Galinier M, Lairez O. Gateway and journey of patients with cardiac amyloidosis. ESC Heart Fail. 2020 Oct;7(5):2418-2430. doi: 10.1002/ehf2.12793. Epub 2020 Jun 26. PMID: 32588554; PMCID: PMC7524246.
Cardiac amyloidosis: What you need to know. Cleveland Clinic. (2025, October 13). https://my.clevelandclinic.org/health/diseases/22598-cardiac-amyloidosis
ClinicalTrials.gov. Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid Cardiomyopathy (ATTRibute-CM). Available at: https://clinicaltrials.gov/study/NCT03860935. [Accessed April 2026]

Friday, May 8, 2026 - 10:24

Sharma Lab Deploys Open-LIFU for Multidisciplinary Neurological Research at NC State, UNC

tim.hodson — Thu, 07 May 2026 15:00:15 +0000

tim.hodson Thu, 05/07/2026 - 10:00

May 7, 2026 — Openwater, an open-source medical technology company has announced a collaboration with the Sharma Lab, a multidisciplinary research group in the Lampe Joint Department of Biomedical Engineering at North Carolina State University and the University of North Carolina at Chapel Hill, focused on designing rehabilitation interventions for people with neurological disorders. The research teams at NC State and UNC-Chapel Hill will deploy Openwater’s open low-intensity focused ultrasound (LIFU) device to study its feasibility and potential effects, including in comparison to invasive procedures such as deep brain stimulation (DBS), or drug-based therapies.

Low-Intensity Focused Ultrasound

Open-LIFU is a portable, noninvasive device that delivers low-intensity focused ultrasound to targeted regions in the body and brain. Led by Nitin Sharma, Ph.D., an associate professor in the Lampe Joint Department of Biomedical Engineering at NC State and UNC-Chapel Hill, the Sharma Lab specializes in rehabilitation engineering and control systems. The researchers plan to study focused ultrasound (FUS) neuromodulation as a potential means to modulate neural activity and assess its effects in patients with spinal cord injuries and neurological disorders.

One application, led by Dr. Irena Dujmovic Basuroski, a multiple sclerosis and neuroimmunology specialist from the University of North Carolina Department of Neurology and the Bodford Family Transverse Myelitis Center, aims to investigate the potential of FUS to improve symptoms in patients with transverse myelitis (TM). TM is a rare disorder in which the spinal cord is inflamed, leading to pain, spasticity (increased muscle tone), mobility complications, and loss of bowel or bladder function. Her research using Open-LIFU is among the first studies to investigate FUS in humans for potential TM symptom relief. The study will specifically focus on patients at a stage where there is a limited chance for more functional recovery.

Dr. Daniel Roque, a movement disorders specialist from the University of North Carolina Department of Neurology, will use Open-LIFU to study essential tremor. His research will investigate temporary modulation of tremor pathways by targeting both the brain and spinal cord with FUS. This approach aims to explore the mechanisms underlying tremor and to better understand how the peripheral and central nervous systems communicate. Existing FUS treatments for tremor often involve tissue ablation and require extensive machinery, which may limit repeatability or broader use. Open-LIFU enables a portable, nonablative, and modular approach to safely test CNS pathways.

“Ultrasound neuromodulation could provide a noninvasive way to modulate spasticity by focusing on pathological circuits in the spinal cord,” said Sharma. “If we can determine that ultrasound is effective in modulating spasticity or essential tremor, it will be very exciting to offer a noninvasive alternative that allows us to more precisely target specific neural circuits.”

Open-LIFU’s adaptable design and open-source software make it suitable for researchers to customize and modify the device for a wide range of research and potential clinical applications. The system is already in active use at U.S. and international institutions like the Massachusetts Institute of Technology (MIT) and Hospital del Mar Research Institute in Barcelona. Early research, including studies from the University of Arizona, suggests potential applications of Open-LIFU for treating neurological disorders, cancer, and mental health disorders like anxiety and depression.

“For decades, treatment development has largely followed a one-disease, one-drug model, often with significant side effects,” said Aaron Timm, CEO of Openwater. “Our partnership with the Sharma Lab and UNC researchers will explore how Open-LIFU may offer a noninvasive way to target specific neural circuits across different conditions, giving researchers and patients a more precise alternative to medication or surgery.”

To learn more about Openwater and its open-source devices, visit www.openwater.health.

Thursday, May 7, 2026 - 10:00

FDA Clears AI Digital Pathology Tool in Breast Cancer

tim.hodson — Thu, 07 May 2026 13:23:00 +0000

tim.hodson Thu, 05/07/2026 - 08:23

May 6, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has received U.S. Food and Drug Administration (FDA) clearance for its ArteraAI Breast for use in patients with early-stage, hormone receptor-positive (HR+), HER2-negative invasive breast cancer.

ArteraAI Breast is the first and only FDA-cleared digital pathology-based risk stratification tool for breast cancer. With clearances in both prostate and breast cancer, Artera continues to expand its platform across additional oncology indications.

These FDA milestones come alongside recent CE Marking for both the ArteraAI Prostate Biopsy Assay and the ArteraAI Breast Cancer Assay, underscoring the company’s expanding regulatory footprint in the U.S. and Europe.

“FDA clearance for ArteraAI Breast represents a significant expansion of our FDA-cleared AI platform in oncology,” said Andre Esteva, CEO and co-founder of Artera. “This milestone reflects the growing role of our technology across multiple cancer types. Breast cancer care is highly nuanced, with treatment decisions that depend on individualized risk. Our goal remains consistent across prostate and breast cancer, and beyond: to help clinicians translate complex data into more precise, personalized treatment decisions across the cancer journey.”

ArteraAI Breast generates an AI-derived risk score that provides prognostic information on the likelihood of distant metastasis in patients with early-stage HR+/HER2- breast cancer. Using digitized histopathology images and patient clinical variables, the model stratifies patients into low- and high-risk groups based on a predefined risk score cutoff.

In early-stage HR+/HER2- breast cancer, determining the appropriate intensity of therapy can be complex due to variability in clinical and pathological factors. By providing consistent, pathology-based risk stratification at the point of diagnosis, ArteraAI Breast is designed to support clinicians in contextualizing risk within established clinical decision-making frameworks.

Data presented at the 2025 San Antonio Breast Cancer Symposium (SABCS) evaluated the model in early-stage breast cancer and demonstrated the potential to inform chemotherapy benefit in certain patient populations.

“This clearance represents an important advance on the road to personalizing treatments for patients with early-stage breast cancer,” said Eric Winer, MD, medical oncologist and director of the Yale Cancer Center. “Using AI and digital pathology has the potential to streamline operational workflows, while creating a strong interdisciplinary linkage between oncology and pathology. This approach may further improve the clinicians' ability to help patients make the best treatment decisions.”

ArteraAI Breast is designed to integrate directly into standard pathology workflows using routine surgical resection samples, without requiring additional tissue or separate specimen collection. This approach allows the software to provide same-day results, enabling pathology labs to provide clinicians with patient-specific prognostic risk information alongside standard histopathology reports.

To learn more, visit artera.ai.

Thursday, May 7, 2026 - 08:23

GE HealthCare Offering ComboTherapy GYN HDR/EBRT for Precision Gynecologic Cancer Care

tim.hodson — Wed, 06 May 2026 18:01:32 +0000

tim.hodson Wed, 05/06/2026 - 13:01

May 6, 2026 — GE HealthCare has announced the availability of MIM ComboTherapy GYN HDR/EBRT², a solution designed to help clinicians plan and evaluate complex radiation therapy treatments for gynecologic cancer with enhanced precision and confidence.

Gynecologic cancers, including cervical and uterine cancers, are often treated using a combination of radiation therapy approaches — most commonly external beam radiation therapy (EBRT) and high-dose-rate (HDR) brachytherapy. While this combination can be highly effective, it also presents a significant clinical challenge: each treatment contributes to the total radiation dose a patient receives, and clinicians must carefully account for prior doses to safely and effectively plan subsequent therapy.

“For far too long, women’s health has not received the focused attention and innovation it deserves — now is the time to intentionally prioritize the unique health needs of women and girls at every stage of life,” shares Shari Manuel, Sales Vice President, U.S. and Canada Imaging, GE HealthCare. “That gap is especially evident in the treatment of gynecologic cancers, where clinicians have historically had to rely on approximations when evaluating cumulative radiation dose — limiting our ability to fully optimize care. Innovations like MIM ComboTherapy GYN HDR/EBRT represent an important step forward, offering a more complete, patient-specific view of dose distribution across therapies. By enabling more personalized, data-driven decision-making, these advances have the potential to improve both treatment outcomes and quality of life for women bravely fighting these cancers.”

GE HealthCare’s MIM ComboTherapy GYN HDR/EBRT addresses this need by providing a comprehensive, visual and quantitative approach to dose summation across treatment modalities — helping enable clinicians to better understand how radiation doses from multiple therapies interact within a patient’s anatomy, and support more informed clinical decision-making.

At the core of the technology is advanced 3D dose summation, incorporating both biological effective dose (BED) and Equivalent Dose in 2 Gy fractions (EQD2), enabling clinicians to assess the biological impact of combined treatments more accurately. By clearly visualizing areas of highest dose accumulation — often referred to as “hotspots” – clinicians can more effectively evaluate treatment plans and optimize therapy delivery.

The solution also includes qualitative and quantitative tools to validate the accuracy of deformable image registration, helping ensure that doses from prior treatments are correctly mapped onto current patient anatomy. This capability is particularly important in gynecologic cases, where anatomical variations — such as those caused by HDR applicators — can complicate treatment planning.

“MIM ComboTherapy GYN HDR/EBRT represents an important step forward in helping clinicians confidently plan complex combination therapies,” says J Anders, General Manager, MIM, GE HealthCare. “By providing a clearer understanding of the total radiation dose a patient receives across treatments, this solution helps clinicians make more informed decisions. As cancer care continues to move toward more personalized, data-driven approaches, innovations like this can play an important role in helping improve treatment planning and outcomes for women undergoing radiation therapy.”

Early clinical evaluations suggest that advanced deformable registration and spatial dose mapping approaches – like those supported by MIM – can provide a clinically viable framework for assessing dose accumulation in gynecologic combination therapy, enabling greater confidence in treatment planning decisions.

The technology is part of the MIM Software portfolio within GE HealthCare’s radiation oncology ecosystem and is designed to integrate seamlessly into existing clinical workflows. With standardized processes, automation, and vendor-neutral compatibility across treatment planning systems, MIM ComboTherap helps streamline plan preparation while maintaining flexibility for diverse clinical environments.

Click here to learn more about GE HealthCare’s portfolio of MIM software solutions.

Johns Hopkins Medicine, “Gynecologic Cancers,” accessed April 14, 2026, https://www.hopkinsmedicine.org/health/conditions-and-diseases/gynecologic-cancers.
MIM ComboTherapy™ GYN HDR/EBRT is available for sale in the United States. Not available in all regions or markets.

Wednesday, May 6, 2026 - 13:01

Researchers Receive Grants from ASRT Foundation

tim.hodson — Wed, 06 May 2026 14:45:34 +0000

tim.hodson Wed, 05/06/2026 - 09:45

May 5, 2026 — The ASRT Foundation recently awarded two emerging researchers with $4,000 each to support medical imaging and radiation therapy students and professionals aspiring to conduct scientific research in the radiologic science profession.

Chad Dall, D.H.Sc., R.T.(R)(MR)

Principal investigator Chad Dall, D.H.Sc., R.T.(R)(MR), was awarded $4,000 for his project “Illuminating Radiology: Using Graphic Novels to Strengthen Student Learning in X-ray Production and Interaction; a Pilot Study.”

Dr. Dall is the director of outreach and engagement and an associate professor of Radiologic Sciences at Bellin College in Green Bay, Wisconsin. He previously served as a magnetic resonance technologist for 10 years at Emplify Health, formerly Bellin Health. With more than 20 years of experience in medical imaging and health care education, Dr. Dall teaches across the radiologic science curriculum. He also contributes to introductory and interdisciplinary coursework, supporting students from high school through upper-level college programs. His background includes extensive work in radiography and magnetic resonance imaging, as well as program development leadership and student engagement initiatives.

Principal investigator Kerry Dunn, Ed.D., R.T.(R)(M), with co-investigator Jennifer Mashburn, M.P.H., R.T.(R)(VI), was awarded $4,000 for their project titled, “Work Environments/Culture and Burnout in Medical Imaging Professionals.”

Kerry Dunn, Ed.D., R.T.(R)(M)

Dr. Dunn is a senior radiography program lecturer and clinical coordinator at Georgia Southern University. She holds a doctoral degree in educational leadership from Georgia State University and a master’s degree from the University of Georgia. With nearly 20 years of experience in radiologic science education, her research focuses on clinical leadership, health equity and burnout. She is dedicated to preparing future medical imaging and radiation therapy professionals through student-centered education.

Co-investigator Jennifer Mashburn, M.P.H., R.T.(R)(VI), is an interventional radiologic technologist with academic training in public health. She was named the 2024 Technologist of the Year by the Georgia Society of Radiologic Technologists. She served as chair of the ASRT Cardiac and Vascular Interventional Chapter and is a two-time president of the Atlanta Society of Radiologic Technologists.

History

The ASRT Foundation began offering the Emerging Researchers Grant in 2021 with funding by ASRT members Rebecca Ludwig, Ph.D., R.T.(R)(QM), FAEIRS, FASRT, Marilyn Sackett, M.Ed., R.T.(R), FASRT, and other contributors.

Wednesday, May 6, 2026 - 09:45